Product-Related Impurities in Clinical-Grade Recombinant AAV Vectors: Characterization and Risk Assessment

Por J. Fraser Wright
Publicado em 2014-03-01

Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman Primates

Por Benjamin J. Samelson-Jones, Jonathan D. Finn, Patricia Favaro, J. Fraser Wright, Valder R. Arruda
Publicado em 2020-06-01